Table 3 Final diagnoses and patient outcomes
Total population n = 870 | Immediate MMT n = 614 (70.6) | Delayed MMT n = 256 (29.4) | p value | |
|---|---|---|---|---|
Pulmonary | 300 (34.5) | 196 (31.9) | 104 (40.6) | 0.02 |
COPD exacerbation | 133 (15.3) | 85 (13.8) | 48 (18.8) | |
Hypoxic pneumonia | 59 (6.8) | 32 (5.2) | 27 (10.5) | |
Asthma exacerbation | 58 (6.6) | 53 (8.6) | 5 (2.0) | |
Other | 37 (4.3) | 17 (2.8) | 20 (7.9) | |
Pulmonary embolism | 9 (1.0) | 5 (0.8) | 4 (1.6) | |
Pleural effusion | 3 (0.3) | 3 (0.5) | 0 (0) | |
Pneumothorax | 1 (0.1) | 1 (0.2) | 0 (0) | |
Cardiovascular | 261 [30] | 181 (29.5) | 80 (31.3) | 0.63 |
Cardiogenic pulmonary edema | 156 (17.9) | 114 (18.6) | 42 (16.4) | |
Global acute heart failure | 23 (2.6) | 10 (1.6) | 13 (5.1) | |
STEMI | 21 (2.4) | 15 (2.4) | 6 (2.3) | |
Chest pain | 19 (2.3) | 15 (2.5) | 4 (1.6) | |
Arrhythmia | 16 (1.8) | 10 (1.6) | 6 (2.4) | |
NSTEMI | 12 (1.4) | 9 (1.5) | 3 (1.2) | |
High-grade AV block | 7 (0.8) | 5 (0.8) | 2 (0.8) | |
Cardiogenic shock | 5 (0.6) | 2 (0.3) | 3 (1.2) | |
Medical cardiac arrest | 2 (0.2) | 1 (0.2) | 1 (0.4) | |
Other | 151 (17.4) | 100 (16.3) | 51 (19.9) | 0.21 |
Anaphylaxis | 74 (8.5) | 69 (11.2) | 5 (2.0) | < 0.001 |
Psychiatrica | 36 (4.1) | 29 (4.7) | 7 (2.7) | 0.10 |
Ear-nose-throatb | 26 (3.0) | 20 (3.3) | 6 (2.3) | 0.66 |
Neuroc | 22 (2.5) | 19 (3.1) | 3 (1.2) | 0.15 |
Mortality | ||||
Day 0 | 51 (5.9) | 26 (4.2) | 25 (9.8) | 0.002 |
Day 7 | 90 (10.3) | 44 (7.2) | 46 [18] | < 0.001 |
Day 30 | 126 (14.5) | 66 (10.7) | 60 (23.4) | < 0.001 |